Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01659658 · ClinicalTrials.gov registry record · Phase 3
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
A Phase 3 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 177
- Enrollment target
NCT01659658 is a Phase 3 study that was terminated before completion, run by Millennium Pharmaceuticals. The registered enrollment target is 177 participants.
The verdict
NCT01659658, a Phase 3 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 177 participants
- Enrollment target
Study Summary
The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB improves hematologic response, 2-year vital organ (that is, heart or kidney) deterioration and mortality rate versus a physician's choice of a chemotherapy regimen in participants diagnosed with relapsed or refractory systemic light chain (AL) amyloidosis.
Interventions
- DRUG Cyclophosphamide
- DRUG Melphalan
- DRUG Dexamethasone
- DRUG Thalidomide
- DRUG IXAZOMIB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2012-12-26 |
| Est. Completion | 2022-07-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01659658
The ClinicalTrials.gov registry entry for NCT01659658 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01659658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01659658 about?
NCT01659658 is a clinical study titled "Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis". The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB improves hematologic response, 2-year vital organ (that is, heart or kidn...
What is the current status of trial NCT01659658?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 177 participants. The study started on 2012-12-26. Estimated completion is 2022-07-11.
What interventions are being tested in trial NCT01659658?
The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Dexamethasone (DRUG), Thalidomide (DRUG), IXAZOMIB (DRUG).
Who is sponsoring clinical trial NCT01659658?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.